Up until this point there has been no treatment for heart failure with preserved pump function that reduced hospitalizations or deaths. New research shows empagliflozin reduces the risk of hospitalization in these patients by about 30% whether they are diabetic or not. This is roughly equivalent with low pump function results and most likely because empagliflozin activates AMPK. What do you think?
The obsession of the “obstructive coronary artery disease” has blinded cardiologists from many natural causes of atherosclerosis, including bone/calcification proliferation due to metabolic disease! Sad…
The obsession of the “obstructive coronary artery disease” has blinded cardiologists from many natural causes of atherosclerosis, including bone/calcification proliferation due to metabolic disease! Sad…